Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis. Pro, B., Kim, Y. H., Ortiz-Romero, P. L., Sokol, L., Scarisbrick, J., Musiek, A., Vermeer, M., Dummer, R., Halwani, A., Fierro, M., Moriya, J., Leoni, M., Bagot, M. AMER SOC CLINICAL ONCOLOGY. 2019

View details for Web of Science ID 000487345806301